Meeting the Demand For GLP-1, GIP, and Glucagon Receptor Agonists

Zeptide Pharma’s 503B Solutions

The healthcare industry is currently facing unprecedented challenges in maintaining a consistent supply of metabolic therapies. At Zeptide Pharma, we are stepping into the gap as a premier manufacturer of sterile GLP-1/GIP/Glucagon receptor agonist injectables.

By leveraging the "drug shortage" exemptions allowed by the FDA under Sections 503A and 503B of the FD&C Act, we ensure that healthcare providers and insurance sectors have access to the critical medications their patients need when commercial versions are unavailable.

Understanding the Regulatory Framework: Sections 503A and 503B

When a medication is listed on the FDA Drug Shortage List, specific provisions within the Federal Food, Drug, and Cosmetic (FD&C) Act allow for the compounding and manufacturing of "essentially a copy" of approved drugs.

  • Section 503B (Outsourcing Facilities): As a specialized manufacturer, Zeptide Pharma operates under cGMP (current Good Manufacturing Practice) standards to produce bulk office-use supply. This is essential for hospitals and clinics that need to maintain stock without individual patient prescriptions.
  • Section 503A (Compounding Pharmacies): These provisions allow for patient-specific prescriptions, ensuring personalized care remains accessible even during global supply chain disruptions.

Advanced Triple Agonist Manufacturing

Zeptide Pharma is at the forefront of metabolic science, focusing on the next generation of therapies. Our sterile injectable facility is equipped to handle:

  • GLP-1 (Glucagon-Like Peptide-1) Agonists
  • GIP (Glucose-Dependent Insulinotropic Polypeptide) Agonists
  • Glucagon Receptor Agonists

By manufacturing these triple agonist and dual-agonist injectables, we provide a comprehensive suite of options for healthcare professional use in managing obesity, type 2 diabetes, and related metabolic syndromes.

A Strategic Partner for the Insurance Sector

The insurance sector and Pharmacy Benefit Managers (PBMs) are increasingly looking for reliable, high-quality alternatives to maintain continuity of care for their members. Zeptide Pharma’s FDA-registered 503B outsourcing facility offers:

  • Cost-Effective Stability: Reducing the reliance on volatile commercial markets.
  • Quality Assurance: Every batch of our sterile GLP-1/GIP injectables undergoes rigorous testing for sterility, potency, and endotoxins.
  • Supply Chain Resilience: Helping payers avoid the high costs associated with untreated chronic conditions due to medication gaps.

Empowering Healthcare Professionals

For the clinician, the "Drug Shortage" exemption is more than a legal clause—it is a lifeline for patient care. Zeptide Pharma provides a reliable office-use supply that allows providers to:

  1. Maintain Treatment Protocols: Avoid switching patients between different medication classes due to stock-outs.
  2. Ensure Safety: Work with a manufacturer that adheres to the highest FDA sterile manufacturing standards.
  3. Streamline Operations: Access bulk supply for in-clinic administration.

Partner with Zeptide Pharma

As a leader in sterile injectable manufacturing, Zeptide Pharma is committed to transparency, regulatory compliance, and clinical excellence. We invite healthcare professionals and insurance providers to contact us to learn more about our current formulary and how our 503B solutions can fortify your clinical supply chain.